Coherus Oncology (CHRS) Competitors $0.88 +0.01 (+1.48%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.88 +0.00 (+0.34%) As of 07/11/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. AMRN, PRTA, CTOR, VOR, AURA, HRTX, SNDL, AVTE, AVIR, and CMPSShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include Amarin (AMRN), Prothena (PRTA), Citius Oncology (CTOR), Vor Biopharma (VOR), Aura Biosciences (AURA), Heron Therapeutics (HRTX), SNDL (SNDL), Aerovate Therapeutics (AVTE), Atea Pharmaceuticals (AVIR), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors Amarin Prothena Citius Oncology Vor Biopharma Aura Biosciences Heron Therapeutics SNDL Aerovate Therapeutics Atea Pharmaceuticals COMPASS Pathways Coherus Oncology (NASDAQ:CHRS) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment. Which has more risk & volatility, CHRS or AMRN? Coherus Oncology has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Amarin has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Which has better valuation and earnings, CHRS or AMRN? Coherus Oncology has higher revenue and earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$266.96M0.38$28.51M-$1.13-0.78Amarin$228.61M1.53-$82.18M-$3.64-4.65 Does the media favor CHRS or AMRN? In the previous week, Amarin had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Amarin and 2 mentions for Coherus Oncology. Amarin's average media sentiment score of 1.34 beat Coherus Oncology's score of 0.94 indicating that Amarin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in CHRS or AMRN? 72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by insiders. Comparatively, 3.3% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is CHRS or AMRN more profitable? Amarin has a net margin of -41.07% compared to Coherus Oncology's net margin of -66.30%. Coherus Oncology's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Coherus Oncology-66.30% N/A -26.51% Amarin -41.07%-17.21%-12.16% Do analysts recommend CHRS or AMRN? Coherus Oncology currently has a consensus price target of $4.68, suggesting a potential upside of 432.20%. Amarin has a consensus price target of $12.00, suggesting a potential downside of 29.12%. Given Coherus Oncology's stronger consensus rating and higher possible upside, equities analysts clearly believe Coherus Oncology is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryCoherus Oncology beats Amarin on 11 of the 16 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.54M$2.96B$5.62B$9.09BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-0.7820.8528.1820.27Price / Sales0.38289.04428.7098.42Price / Cash2.9742.8637.4658.16Price / Book-0.777.638.045.49Net Income$28.51M-$55.05M$3.19B$250.45M7 Day Performance9.86%8.43%3.62%4.79%1 Month Performance11.34%5.42%4.06%7.68%1 Year Performance-46.99%2.03%30.01%16.43% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology3.8087 of 5 stars$0.88+1.5%$4.68+432.2%-45.3%$100.54M$266.96M-0.78330News CoverageAMRNAmarin0.4447 of 5 stars$16.65-0.5%$12.00-27.9%+13.5%$344.77M$214.11M-4.57360Positive NewsPRTAProthena3.5759 of 5 stars$6.29-2.2%$31.50+400.8%-71.4%$338.59M$135.16M-3.02130CTORCitius Oncology0.3687 of 5 stars$4.71-11.0%$3.00-36.3%N/A$337.01MN/A0.00N/ANews CoverageGap DownVORVor Biopharma3.9134 of 5 stars$2.67+39.8%$5.63+110.8%+155.2%$333.64MN/A-1.62140Options VolumeHigh Trading VolumeAURAAura Biosciences2.5811 of 5 stars$6.16-6.1%$22.00+257.1%-22.7%$329.77MN/A-3.2450Positive NewsHRTXHeron Therapeutics3.6831 of 5 stars$2.15-2.3%$5.00+132.6%-34.1%$328.00M$144.29M-35.83300Gap DownSNDLSNDL3.0531 of 5 stars$1.24-2.4%$3.63+192.3%-36.2%$325.84M$927.61M-4.282,516News CoverageAVTEAerovate TherapeuticsN/A$11.14+3.1%N/A-84.0%$322.89MN/A-3.7320High Trading VolumeAVIRAtea Pharmaceuticals2.7409 of 5 stars$3.64-2.7%$6.00+64.8%+8.9%$311.51MN/A-2.2170News CoveragePositive NewsCMPSCOMPASS Pathways1.8329 of 5 stars$3.31+1.5%$17.00+413.6%-49.2%$309.68MN/A-1.66120 Related Companies and Tools Related Companies Amarin Alternatives Prothena Alternatives Citius Oncology Alternatives Vor Biopharma Alternatives Aura Biosciences Alternatives Heron Therapeutics Alternatives SNDL Alternatives Aerovate Therapeutics Alternatives Atea Pharmaceuticals Alternatives COMPASS Pathways Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRS Stock Alerts